Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31060758 | 1.00 | PLD2 (1.00) | PLD2PLD1 | |
| SCHEMBL14845989 | 0.93 | PLD2 (1.00) | PLD2PLD1 | |
| SCHEMBL14845986 | 0.90 | PLD2 (1.00) | PLD2PLD1 | |
| SCHEMBL14845985 | 0.89 | PLD2 (1.00) | PLD2PLD1 | |
| SCHEMBL11718350 | 0.88 | PLD2 (1.00) | PLD2PLD1 | |
| SCHEMBL14846012 | 0.88 | PLD2 (1.00) | PLD2PLD1 | |
| SCHEMBL14846008 | 0.88 | PLD2 (1.00) | PLD2PLD1 | |
| SCHEMBL10311349 | 0.87 | PLD2 (1.00) | PLD2PLD1 | |
| SCHEMBL11721660 | 0.87 | PLD2 (1.00) | PLD2PLD1 | |
| SCHEMBL11768171 | 0.87 | PLD2 (1.00) | PLD2PLD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160271114-A1 | Composition for preventing or treating bacterial infectious disease comprising phospholipase D2 inhibitor | Research & Business Foundation Sungkyunkwan University (KR) | 2016-09-22 | — | — | US | claimed |
| US-9267122-B2 | Modulation of phospholipase D for the treatment of neurodegenerative disorders | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2016-02-23 | — | — | US | claimed |
| US-20120178719-A1 | MODULATION OF PHOSPHOLIPASE D FOR THE TREATMENT OF NEURODEGENERATIVE DISORDERS | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2012-07-12 | — | — | US | claimed |
| CN-102459584-A | Modulation of phospholipase d for treatment of neurodegenerative disorders | UNIV COLUMBIA | 2012-05-16 | — | — | CN | claimed |
| EP-2435563-A1 | MODULATION OF PHOSPHOLIPASE D FOR THE TREATMENT OF NEURODEGENERATIVE DISORDERS | The Trustees of Columbia University in the City of New York (US) | 2012-04-04 | — | — | EP | claimed |
| WO-2010138869-A1 | MODULATION OF PHOSPHOLIPASE D FOR THE TREATMENT OF NEURODEGENERATIVE DISORDERS | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2010-12-02 | — | — | WO | claimed |
| US-10039715-B2 | Liposomal formulation of nonglycosidic ceramides and uses thereof | LUDWIG INSTITUTE FOR CANCER RESEARCH LTD. (US) | 2018-08-07 | — | — | US | disclosed |
| EP-2654779-B1 | LIPOSOMAL FORMULATION OF NONGLYCOSIDIC CERAMIDES AND USES THEREOF | LUDWIG INST FOR CANCER RES LTD (US) | 2018-02-28 | — | — | EP | disclosed |
| US-20170319611-A1 | METHODS AND COMPOSITIONS COMPRISING AKT INHIBITORS AND/OR PHOSPHOLIPASE D INHIBITORS | UNIV VANDERBILT (US) | 2017-11-09 | — | — | US | disclosed |
| US-20170105936-A1 | LIPOSOMAL FORMULATION OF NONGLYCOSIDIC CERAMIDES AND USES THEREOF | LUDWIG INSTITUTE FOR CANCER RESEARCH LTD. (US) | 2017-04-20 | — | — | US | disclosed |
| US-20160296506-A1 | Methods and Compositions for Treating HIV Infection | VANDERBILT UNIVERSITY | 2016-10-13 | — | — | US | disclosed |
| US-20160296506-A1 | Methods and Compositions for Treating HIV Infection | VANDERBILT UNIVERSITY | 2016-10-13 | — | — | US | disclosed |
| US-9453017-B2 | Antiviral therapies with phospholipase D inhibitors | VANDERBILT UNIVERSITY (US) | 2016-09-27 | — | — | US | disclosed |
| US-20120178719-A1 | MODULATION OF PHOSPHOLIPASE D FOR THE TREATMENT OF NEURODEGENERATIVE DISORDERS | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2012-07-12 | — | — | US | disclosed |
| US-20120178719-A1 | MODULATION OF PHOSPHOLIPASE D FOR THE TREATMENT OF NEURODEGENERATIVE DISORDERS | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2012-07-12 | — | — | US | disclosed |
| WO-2012088414-A1 | LIPOSOMAL FORMULATION OF NONGLYCOSIDIC CERAMIDES AND USES THEREOF | LUDWIG INSTITUTE FOR CANCER RESEARCH LTD. (US) | 2012-06-28 | — | — | WO | disclosed |
| WO-2012064072-A2 | COMPOSITION FOR PREVENTING OR TREATING RHEUMATOID ARTHRITIS COMPRISING A PHOSPHOLIPASE D1 INHIBITOR AS AN ACTIVE INGREDIENT | 부산대학교 산학협력단 (KR) | 2012-05-18 | — | — | WO | disclosed |
| CN-102459584-A | Modulation of phospholipase d for treatment of neurodegenerative disorders | UNIV COLUMBIA | 2012-05-16 | — | — | CN | disclosed |
| EP-2435563-A1 | MODULATION OF PHOSPHOLIPASE D FOR THE TREATMENT OF NEURODEGENERATIVE DISORDERS | The Trustees of Columbia University in the City of New York (US) | 2012-04-04 | — | — | EP | disclosed |
| WO-2010138869-A1 | MODULATION OF PHOSPHOLIPASE D FOR THE TREATMENT OF NEURODEGENERATIVE DISORDERS | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2010-12-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170105936-A1 | LIPOSOMAL FORMULATION OF NONGLYCOSIDIC CERAMIDES AND USES THEREOF | CERS2, CERT1, SGMS1 | PLD2 201/4885PLD1 184/4885 |
| US-20160296506-A1 | Methods and Compositions for Treating HIV Infection | SMPD3, PLD3, SMPD1 | PLD2 5/4885PLD1 4/4885 |
| US-10039715-B2 | Liposomal formulation of nonglycosidic ceramides and uses thereof | CERS2, CERT1, SGMS1 | PLD2 201/4885PLD1 184/4885 |
| US-20170319611-A1 | METHODS AND COMPOSITIONS COMPRISING AKT INHIBITORS AND/OR PHOSPHOLIPASE D INHIBITORS | PLD1, PLD2, PIK3CD | PLD2 2/4885PLD1 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.